{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:24:15Z","timestamp":1754144655571,"version":"3.41.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.7759\/cureus.88015","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:58:56Z","timestamp":1752605936000},"source":"Crossref","is-referenced-by-count":0,"title":["Extensive Arteriovenous Fistula Thrombosis With Glucagon-Like Peptide-1 Agonist"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Muneeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralys","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanika","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Bhura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghadeer","family":"Hannoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12132","article-title":"KHA-CARI Guideline: vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts","volume":"18","author":"Polkinghorne KR","year":"2013","unstructured":"Polkinghorne KR, Chin GK, MacGinley RJ, et al.. KHA-CARI Guideline: vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts. Nephrology (Carlton). 2013, 18:701-5. 10.1111\/nep.12132","journal-title":"Nephrology (Carlton)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.46747\/cfp.6808577","article-title":"Overview of hemodialysis access and assessment","volume":"68","author":"Arasu R","year":"2022","unstructured":"Arasu R, Jegatheesan D, Sivakumaran Y. Overview of hemodialysis access and assessment. Can Fam Physician. 2022, 68:577-82. 10.46747\/cfp.6808577","journal-title":"Can Fam Physician"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000526768","article-title":"Risk factors for arteriovenous fistula thrombus development: a systematic review and meta-analysis","volume":"47","author":"Zhang Y","year":"2022","unstructured":"Zhang Y, Yi J, Zhang R, Peng Y, Dong J, Sha L. Risk factors for arteriovenous fistula thrombus development: a systematic review and meta-analysis. Kidney Blood Press Res. 2022, 47:643-53. 10.1159\/000526768","journal-title":"Kidney Blood Press Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.536","article-title":"The risk of thromboembolic events in kidney transplant patients","volume":"85","author":"Verhave JC","year":"2014","unstructured":"Verhave JC, Tagalakis V, Suissa S, Madore F, H\u00e9bert MJ, Cardinal H. The risk of thromboembolic events in kidney transplant patients. Kidney Int. 2014, 85:1454-60. 10.1038\/ki.2013.536","journal-title":"Kidney Int"},{"key":"ref5","article-title":"Deep Venous Thrombosis Risk Factors","author":"McLendon K","year":"2025","unstructured":"McLendon K, Goyal A, Attia M. Deep Venous Thrombosis Risk Factors. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.11.052","article-title":"Diabetes mellitus and thrombosis","volume":"129","author":"Vazzana N","year":"2012","unstructured":"Vazzana N, Ranalli P, Cuccurullo C, Dav\u00ec G. Diabetes mellitus and thrombosis. Thromb Res. 2012, 129:371-7. 10.1016\/j.thromres.2011.11.052","journal-title":"Thromb Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2023.03.004","article-title":"Diabetic kidney disease: an update","volume":"107","author":"Gupta S","year":"2023","unstructured":"Gupta S, Dominguez M, Golestaneh L. Diabetic kidney disease: an update. Med Clin North Am. 2023, 107:689-705. 10.1016\/j.mcna.2023.03.004","journal-title":"Med Clin North Am"},{"key":"ref8","unstructured":"International Diabetes Federation. Diabetes now affects one in 10 adults worldwide. (2021). Accessed. May 14, 2025: https:\/\/idf.org\/news\/diabetes-now-affects-one-in-10-adults-worldwide\/."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.2026","article-title":"Prescription fills for semaglutide products by payment method","volume":"5","author":"Scannell C","year":"2024","unstructured":"Scannell C, Romley J, Myerson R, Goldman D, Qato DM. Prescription fills for semaglutide products by payment method. JAMA Health Forum. 2024, 5:e242026. 10.1001\/jamahealthforum.2024.2026","journal-title":"JAMA Health Forum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.022","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): outcomes by sex","volume":"84","author":"Verma S","year":"2024","unstructured":"Verma S, Colhoun HM, Dicker D, et al.. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): outcomes by sex. J Am Coll Cardiol. 2024, 84:1678-82. 10.1016\/j.jacc.2024.08.022","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.037775","article-title":"Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6","volume":"53","author":"Strain WD","year":"2022","unstructured":"Strain WD, Frenkel O, James MA, et al.. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022, 53:2749-57. 10.1161\/STROKEAHA.121.037775","journal-title":"Stroke"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5339\/qmj.2024.75","article-title":"Portal vein thrombosis in a patient on semaglutide","volume":"2024","author":"Farooqi MF","year":"2024","unstructured":"Farooqi MF, Khan M, Muhammad AM, Agha A. Portal vein thrombosis in a patient on semaglutide. Qatar Med J. 2024, 2024:75. 10.5339\/qmj.2024.75","journal-title":"Qatar Med J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50051","article-title":"An atypical presentation of dulaglutide-induced pancreatitis complicated by superior mesenteric vein thrombosis","volume":"15","author":"Manuel SL","year":"2023","unstructured":"Manuel SL, Lin F, Kutty SM. An atypical presentation of dulaglutide-induced pancreatitis complicated by superior mesenteric vein thrombosis. Cureus. 2023, 15:e50051. 10.7759\/cureus.50051","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2024.08.011","article-title":"Extensive deep vein thrombosis in a young man taking tirzepatide for weight loss","volume":"10","author":"Farooqi MF","year":"2024","unstructured":"Farooqi MF, Mehmood MA, Khan M, Salman HM, Agha A. Extensive deep vein thrombosis in a young man taking tirzepatide for weight loss. AACE Clin Case Rep. 2024, 10:261-3. 10.1016\/j.aace.2024.08.011","journal-title":"AACE Clin Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dbi16-0014","article-title":"Glucagon-like peptide 1 receptor activation and platelet function: beyond glycemic control","volume":"65","author":"Jia G","year":"2016","unstructured":"Jia G, Aroor AR, Sowers JR. Glucagon-like peptide 1 receptor activation and platelet function: beyond glycemic control. Diabetes. 2016, 65:1487-9. 10.2337\/dbi16-0014","journal-title":"Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1141","article-title":"Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis","volume":"65","author":"Cameron-Vendrig A","year":"2016","unstructured":"Cameron-Vendrig A, Reheman A, Siraj MA, et al.. Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis. Diabetes. 2016, 65:1714-23. 10.2337\/db15-1141","journal-title":"Diabetes"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ21-0129","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin DG","year":"2021","unstructured":"Yin DG, Ding LL, Zhou HR, Qiu M, Duan XY. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. Endocr J. 2021, 68:739-42. 10.1507\/endocrj.EJ21-0129","journal-title":"Endocr J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372748-extensive-arteriovenous-fistula-thrombosis-with-glucagon-like-peptide-1-agonist","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:58:57Z","timestamp":1752605937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372748-extensive-arteriovenous-fistula-thrombosis-with-glucagon-like-peptide-1-agonist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.88015","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}